Efficacy of a CBT Self-Help App (Zemedy) Versus an Education, Relaxation, and Mindfulness App for IBS: Results from Post-Treatment, 3-Month, and 6-Month Follow-Up.

J Clin GastroenterolMar 12, 2025 (epub)

Melissa Hunt, Anika Dalvie, Simay Ipek et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared the Zemedy self-help cognitive behavioral therapy (CBT) app with an active app providing education, lifestyle management, relaxation, and mindfulness for people with irritable bowel syndrome. Of 267 participants who downloaded an assigned app, 136 received CBT and 131 the control. At post-treatment, intention-to-treat analyses found significantly greater improvement with CBT in both primary outcomes—IBS symptom severity and quality of life—and in secondary outcomes except depression. Improvements were reported as maintained at 3 and 6 months, but follow-up attrition was considerable.

Key findings

  • At post-treatment, CBT produced significantly greater improvement than the active control in IBS symptom severity and IBS quality of life.
  • CBT improved secondary outcomes more than control except depression; the control group improved on all outcomes except fear of food.
  • Gains were maintained at 3 and 6 months, although follow-up numbers declined to 65 and 32, respectively.

Why it matters

The findings suggest that app-delivered self-help CBT may offer benefits beyond education, relaxation, and mindfulness, including for psychological factors associated with IBS. The active comparator also improved on several outcomes, underscoring that symptom-management education and relaxation-based content may be useful components. The results support further consideration of digital CBT while highlighting uncertainty from attrition and unmeasured app engagement.

What to keep in mind

Follow-up attrition was considerable, and the study did not collect data on app engagement.

Source

Published in J Clin Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.